New hope for High-Risk pancreatic cancer patients in major trial
NCT ID NCT07277452
Summary
This study is testing if adding a drug called nimotuzumab to standard chemotherapy helps people with high-risk pancreatic cancer that can be removed by surgery. About 156 patients will receive the drug combination or a placebo before and after their operation. The main goal is to see if this approach keeps the cancer from coming back longer and helps patients live longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chunyi Hao
Beijing, 100000, China
Contact
Contact
-
Kuirong Jiang
Nanjing, Jiangsu, 210029, China
Contact
Conditions
Explore the condition pages connected to this study.